Lysine deacetylation in ischaemic preconditioning: The role of SIRT1

Cardiovascular Research

Volumn 89, Issue 3, 2011, Pages 643-649

  Nadtochiy, Sergiy M ^a   Redman, Emily ^a   Rahman, Irfan ^a   Brookes, Paul S ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Ischaemia; Lysine acetylation; Preconditioning; Sirtuins; SUMO

Indexed keywords

DAPORINAD; HYDROLASE INHIBITOR; LYSINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN 1; SPLITOMICIN; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEACETYLATION; ENZYME INHIBITION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; ISOLATED HEART; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REPERFUSION INJURY; SUMOYLATION; WESTERN BLOTTING;

ACETYLATION; ANIMALS; DISEASE MODELS, ANIMAL; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LYSINE; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; NAD; SIRTUIN 1;

EID: 79551470041     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq287     Document Type: Article

References (66)

1. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008;88:581-609.
2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
3. Rizvi A, Tang XL, Qiu Y, Xuan YT, Takano H, Jadoon AK et al. Increased protein synthesis is necessary for the development of late preconditioning against myocardial stunning. Am J Physiol 1999;277:H874-H884. (Pubitemid 29459599)
4. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol 2005;288:H971-H976.
5. Nadtochiy SM, Burwell LS, Brookes PS. Cardioprotection and mitochondrial S-nitrosation: effects of S-nitroso-2-mercaptopropionyl glycine (SNO-MPG) in cardiac ischemia-reperfusion injury. J Mol Cell Cardiol 2007;42:812-825.
6. Sun J, Morgan M, Shen RF, Steenbergen C, Murphy E. Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport. Circ Res 2007;101:1155-1163.
7. Lu Z, Scott I, Webster BR, Sack MN. The emerging characterization of lysine residue deacetylation on the modulation of mitochondrial function and cardiovascular biology. Circ Res 2009;105:830-841.
8. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009;41:185-198.
9. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone dea-cetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370:737-749.
10. Suzuki YJ, Nagase H, Day RM, Das DK. GATA-4 regulation of myocardial survival in the preconditioned heart. J Mol Cell Cardiol 2004;37:1195-1203.
11. Zhao TC, Cheng G, Zhang LX, Tseng YT, Padbury JF. Inhibition of histone deacety-lases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc Res 2007;76:473-481.
12. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009;460:587-591.
13. Yu J, Auwerx J. Protein deacetylation by SIRT1: an emerging key post-translational modification in metabolic regulation. Pharmacol Res 2009;62:35-41.
14. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2007;104:14855-14860.
15. Zhang J. The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem 2007;282:34356-34364.
16. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA 2008;105:3374-3379.
17. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007;100:1512-1521.
18. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303:2011-2015.
19. van der HA, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, Burgering BM. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 2004;279:28873-28879.
20. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 2005;24:1021-1032.
21. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 2009;324:1289-1293.
22. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004;23:2369-2380.
23. Danz ED, Skramsted J, Henry N, Bennett JA, Keller RS. Resveratrol prevents doxor-ubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 2009;46:1589-1597.
24. Pillai JB, Isbatan A, Imai S, Gupta MP. Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 2005;280:43121-43130.
25. Hsu CP, Oka S, Shao D, Hariharan N, Sadoshima J. Nicotinamide phosphoribosyl-transferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res 2009;105:481-491.
26. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotina-mide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004;279:50754-50763.
27. Prime TA, Blaikie FH, Evans C, Nadtochiy SM, James AM, Dahm CC et al. A mitochondria-targeted S-nitrosothiol modulates respiration, nitrosates thiols, and protects against ischemia-reperfusion injury. Proc Natl Acad Sci USA 2009;106: 10764-10769.
28. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 2001;98:15113-15118.
29. Hirao M, Posakony J, Nelson M, Hruby H, Jung M, Simon JA et al. Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screens in yeast. J Biol Chem 2003;278:52773-52782.
30. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nico-tinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-7442.
31. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450:712-716.
32. Nadtochiy SM, Burwell LS, Ingraham CA, Spencer CM, Friedman AE, Pinkert CA et al. In vivo cardioprotection by S-nitroso-2-mercaptopropionyl glycine. J Mol Cell Cardiol 2009;46:960-968.
33. Cox B, Emili A. Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat Protoc 2006;1:1872-1878.
34. Tompkins AJ, Burwell LS, Digerness SB, Zaragoza C, Holman WL, Brookes PS. Mito-chondrial dysfunction in cardiac ischemia-reperfusion injury: ROS from complex I, without inhibition. Biochim Biophys Acta 2006;1762:223-231.
35. Nadtochiy SM, Tompkins AJ, Brookes PS. Different mechanisms of mitochondrial proton leak in ischaemia/reperfusion injury and preconditioning: implications for pathology and cardioprotection. Biochem J 2006;395:611-618.
36. Garlid KD, Costa AD, Quinlan CL, Pierre SV, Dos SP. Cardioprotective signaling to mitochondria. J Mol Cell Cardiol 2009;46:858-866.
37. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, Cohen MV et al. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 2005;97:329-336.
38. Eaton P, Awad WI, Miller JI, Hearse DJ, Shattock MJ. Ischemic preconditioning: a potential role for constitutive low molecular weight stress protein translocation and phosphorylation? J Mol Cell Cardiol 2000;32:961-971.
39. Malik G, Gorbounov N, Das S, Gurusamy N, Otani H, Maulik N et al. Ischemic preconditioning triggers nuclear translocation of thioredoxin and its interaction with Ref-1 potentiating a survival signal through the PI-3-kinase-Akt pathway. Antioxid Redox Signal 2006;8:2101-2109.
40. Pyle WG, Chen Y, Hofmann PA. Cardioprotection through a PKC-dependent decrease in myofilament ATPase. Am J Physiol 2003;285:H1220-H1228.
41. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002;21:2383-2396.
42. Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, DiStefano PS et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 2006;26:28-38.
43. Vaziri H, Dessain SK, Ng EE, Imai SI, Frye RA, Pandita TK et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-159.
44. Luss H, Schmitz W, Neumann J. A proteasome inhibitor confers cardioprotection. Cardiovasc Res 2002;54:140-151.
45. Sasaki T, Maier B, Koclega KD, Chruszcz M, Gluba W, Stukenberg PT et al. Phos-phorylation regulates SIRT1 function. PLoS One 2008;3:e4020.
46. Yang Y, Fu W, Chen J, Olashaw N, Zhang X, Nicosia SV et al. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol 2007;9:1253-1262.
47. Ja LY, Castri P, Bembry J, Maric D, Auh S, Hallenbeck JM. SUMOylation participates in induction of ischemic tolerance. J Neurochem 2009;109:257-267.
48. Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009;104:879-886.
49. Pacholec M, Chrunyk BA, Cunningham D, Flynn D, Griffith DA, Griffor M et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010;285:8340-8351.
50. Das S, Das DK. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2007;2:133-138.
51. Penumathsa SV, Maulik N. Resveratrol: a promising agent in promoting cardioprotec-tion against coronary heart disease. Can J Physiol Pharmacol 2009;87:275-286.
52. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009;74:619-624.
53. Borra MT, Langer MR, Slama JT, Denu JM. Substrate specificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/protein deacetylases. Biochemistry 2004;43:9877-9887.
54. Rajamohan SB, Pillai VB, Gupta M, Sundaresan NR, Birukov KG, Samant S et al. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol 2009;29:4116-4129.
55. Liaudet L, Yang Z, Al-Affar EB, Szabo C. Myocardial ischemic preconditioning in rodents is dependent on poly (ADP-ribose) synthetase. Mol Med 2001;7:406-417.
56. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008;321:1493-1495.
57. Nishino Y, Miura T, Miki T, Sakamoto J, Nakamura Y, Ikeda Y et al. Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res 2004;61:610-619.
58. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC et al. AMPK regulates energy expenditure by modulating NAD + metabolism and SIRT1 activity. Nature 2009;458:1056-1060.
59. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A et al. A role for the mitochon-drial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 2008; 105:14447-14452.
60. Burwell LS, Nadtochiy SM, Brookes PS. Cardioprotection by metabolic shut-down and gradual wake-up. J Mol Cell Cardiol 2009;46:804-810.
61. Caito S, Rajendrasozhan S, Cook S, Chung S, Yao H, Friedman AE et al. SIRT1 is a redox-sensitive deacetylase that is post-translationally modified by oxidants and car-bonyl stress. FASEB J 2010;24:3145-3159.
62. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:861-870.
63. Zee RS, Yoo CB, Pimentel DR, Perlman DH, Burgoyne JR, Hou X et al. Redox regulation of sirtuin-1 is mediated by S-glutathiolation. Antioxid Redox Signal 2010;13:1023-1032.
64. Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S et al. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 2010;285:8375-8382.
65. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009;324:1076-1080.
66. Yang SR, Wright J, Bauter M, Seweryniak K, Kode A, Rahman I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo implications for chronic inflammation and aging. Am J Physiol 2007;292:L567-L576.